MapLight Therapeutics (MPLT): The Best Healthcare Stock Insiders Are Buying

On April 7, 2026, TD Cowen initiated sum of MapLight Therapeutics with a Buy rating, highlighting its pipeline targeting cardinal tense strategy and neuropsychiatric conditions. TD Cowen said the pb plus ML-007C-MA is positioned to amended connected Cobenfy’s illustration successful schizophrenia, with a Phase II readout expected successful Q3, and views the shares arsenic undervalued based connected this opportunity.

Last month, Canaccord initiated sum of MapLight Therapeutics with a Buy standing and a $35 terms target. Canaccord said the company’s absorption connected caller CNS therapeutics supports its schizophrenia accidental and recommends buying the banal up of Phase 2 information for ML-007C-MA expected successful Q3.

MapLight Therapeutics, Inc. (NASDAQ:MPLT) develops therapies for cardinal tense strategy disorders.

While we admit the imaginable of MPLT arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey connected Google News.